Schlieren/Zurich, Switzerland, October 13, 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has further enhanced its Management Team by appointing Peter Harboe-Schmidt as Chief Financial Officer (CFO).
Peter brings a broad industry, finance, corporate development and Start-Up experience to CUTISS. He was, among others, Co-Founder and CEO of Xigen Pharma (Ecublens/Lausanne) and Co-Founder of SpiroChem (Basel). In addition, at Innosuisse, he was a Head Coach and regularly coached founders and CEO’s of young Swiss-based Life Science companies. Peter started his professional career in various positions at Amgen Europe and DuPont de Nemours. Besides his new professional challenge at CUTISS, he continues to serve as executive Chairman of SpiroChem. Peter has a Master in Chemical Engineering from the Technical University of Denmark (Copenhagen) as well as an MBA from IMD Lausanne. He is a Danish and Swiss citizen.
Peter Harboe-Schmidt said: “I am pleased by the opportunity of joining CUTISS, and I am very excited and committed to supporting the Company in achieving its next milestones.” Dr. Daniela Marino, CEO and Co-Founder of CUTISS AG, added: “We are very happy that Peter is on board, further developing our Company and bringing additional and valuable competences to the Management Team.”
About CUTISS AG
CUTISS is a Swiss Life Science Company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich; denovoSkin™ was well tolerated by all patients with no safety issue reported. Phase II studies are currently ongoing in Switzerland and the European Union and are partially funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ aims to improve life quality of elective (reconstructive treatments) patients as well and it can further be developed in terms of complexity by adding pigmentation. CUTISS ranked #1 in the 2020 “Top 100 Swiss Startup Award” competition. www.cutiss.swiss
CUTISS AG, CEO Dr. Daniela Marino, +41 44 244 36 60, firstname.lastname@example.org